Question

After which phase of clinical trials do pharmaceutical companies submit a New Drug Application (NDA) to the regulatory authority?

• A. Phase I
• B. Phase II
• C. Phase III
• D. Phase IV

Hint:

Remember: NDA submission follows successful Phase III trials, while Phase IV studies are post-marketing studies conducted after drug approval.

Answer 1

The Correct Option is C

A New Drug Application (NDA) is submitted to the regulatory authority (such as the US FDA or CDSCO in India) after the successful completion of Phase III clinical trials. The NDA is a formal request to approve a new pharmaceutical for marketing and includes comprehensive data on: - Preclinical (animal) studies
- Chemistry, Manufacturing, and Controls (CMC)
- Pharmacokinetics and pharmacodynamics
- Safety and efficacy data from Phase I to Phase III trials
Let’s review the phases briefly: - Phase I: Assesses safety, dosage, and pharmacokinetics in a small group of healthy volunteers.
- Phase II: Evaluates efficacy and side effects in patients with the disease/condition.
- Phase III: Confirms therapeutic effect in a larger patient population and compares with standard treatments.
- Phase IV: Conducted after NDA approval for post-marketing surveillance and long-term side effects.
Thus, the NDA is submitted after Phase III but before Phase IV begins.

Answer 2

Drug development moves through defined clinical trial phases before a company can ask a regulator to approve the drug for sale. Walking through what each phase actually accomplishes shows exactly where the NDA submission fits.

1. Phase I: Phase I tests a small group of healthy volunteers mainly to check safety, tolerability, and basic pharmacokinetics. At this stage there is not nearly enough efficacy data to support an NDA.
2. Phase II: Phase II moves into a modest number of actual patients to get an early read on whether the drug works and to refine dosing. This is still exploratory, without the large-scale confirmatory evidence regulators need.
3. Phase III: Phase III enrolls large patient populations, often across multiple sites, to confirm efficacy and safety against standard treatment or placebo. Once this phase generates enough robust safety and efficacy data, the company compiles it, along with preclinical and manufacturing data, into the New Drug Application for regulatory review.
4. Phase IV: Phase IV is post-marketing surveillance, conducted only after the drug is already approved and being sold, so it happens after the NDA has already been submitted and cleared, not before.

The confirmatory, large-scale evidence needed for an NDA only exists once Phase III trials are complete.

So the correct answer is Phase III.